Inspirata

Caradigm specializes in intelligent healthcare analytics and population health management solutions. The company provides an enterprise platform that includes visual analytics and care management services, all hosted in the cloud. These offerings are designed to assist healthcare organizations in enhancing patient care, minimizing costs, and effectively managing risk. By delivering insights into patients, populations, and overall performance, Caradigm aims to support healthcare providers in navigating the complexities of modern healthcare delivery.

Omnyx, LLC is a joint venture between GE Healthcare and UPMC, with operations based in Pittsburgh, PA, and Piscataway, NJ. The company specializes in digital pathology solutions, particularly the Omnyx IDP system, which facilitates an all-digital workflow for pathology departments worldwide. Omnyx offers a range of products, including image acquisition devices, workflow software, and consulting services aimed at transforming cancer care. By closely collaborating with pathologists at UPMC and other institutions, as well as leveraging its relationship with GE Healthcare, Omnyx focuses on addressing the specific needs of anatomic pathologists globally. Its products are designed for in vitro diagnostic use in particular clinical applications, while also allowing for research use in other areas.

Artificial Intelligence in Medicine, Inc. is a Toronto-based software engineering firm that specializes in developing tools that utilize artificial intelligence (AI) and natural language processing (NLP) to enhance healthcare delivery, particularly in cancer control. The company focuses on extracting relevant information from various clinical documents, including pathology reports and treatment plans, to support medical research and disease prevention efforts. By designing and deploying advanced information systems, Artificial Intelligence in Medicine aims to improve healthcare services and patient outcomes in the oncology sector. Incorporated in 1983, the firm operates as a subsidiary of Inspirata, Inc., continuing its commitment to integrating informatics into healthcare solutions.

Precision Medicine Network was co-founded in 2011 by Richard Kellner, CEO, and Dr. Mark Boguski, CMO. PMNI was an outgrowth of the Genomic Medicine Initiative at Harvard Medical School in 2009. The company’s mission is to provide “Fluency in the language of Precision Medicine™” as a basis of connecting providers, patients and payers to overcome barriers and realize the potential of precision healthcare. This is accomplished through “Crosswalk Insight™: Oncology,” a platform designed to accelerate the rational adoption of precision medicine. Current users of the system include medical, surgical and radiation oncologists, pathologists and laboratory medicine professionals, pharmaceutical companies, clinical trial developers, diagnostics companies, life science toolmakers, health system executives, medical students, residents and fellows, and oncology nurses and genetic counselors.